Oneness Biotech Co Ltd (4743) - Total Liabilities
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has total liabilities worth NT$872.39 Million TWD (≈ $27.49 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Oneness Biotech Co Ltd to track the company's year-over-year net asset growth rate.
Oneness Biotech Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 4743 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Oneness Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Oneness Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VersaBank
TO:VBNK
|
Canada | CA$5.89 Billion |
|
Shenyang Jinbei Automotive Co Ltd
SHG:600609
|
China | CN¥2.29 Billion |
|
Wolong Real Estate Group Co Ltd
SHG:600173
|
China | CN¥4.13 Billion |
|
Latham Group Inc
NASDAQ:SWIM
|
USA | $459.70 Million |
|
ACLARA RESOURCES INC.
F:JD1
|
Germany | €10.94 Million |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507
|
China | CN¥325.04 Million |
|
Vanjee Technology Co Ltd
SHE:300552
|
China | CN¥958.76 Million |
|
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
|
China | CN¥7.72 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Oneness Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4743 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 37.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oneness Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual total liabilities of Oneness Biotech Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$859.65 Million ≈ $27.08 Million |
-0.78% |
| 2023-12-31 | NT$866.43 Million ≈ $27.30 Million |
+23.71% |
| 2022-12-31 | NT$700.38 Million ≈ $22.07 Million |
-57.34% |
| 2021-12-31 | NT$1.64 Billion ≈ $51.72 Million |
+1.05% |
| 2020-12-31 | NT$1.62 Billion ≈ $51.18 Million |
+211.85% |
| 2019-12-31 | NT$520.96 Million ≈ $16.41 Million |
+207.09% |
| 2018-12-31 | NT$169.64 Million ≈ $5.34 Million |
+541.03% |
| 2017-12-31 | NT$26.46 Million ≈ $833.76K |
-15.74% |
| 2016-12-31 | NT$31.41 Million ≈ $989.49K |
-24.71% |
| 2015-12-31 | NT$41.72 Million ≈ $1.31 Million |
-47.77% |
| 2014-12-31 | NT$79.87 Million ≈ $2.52 Million |
-35.50% |
| 2013-12-31 | NT$123.82 Million ≈ $3.90 Million |
+478.35% |
| 2012-12-31 | NT$21.41 Million ≈ $674.50K |
+6.59% |
| 2011-12-31 | NT$20.09 Million ≈ $632.79K |
+7.72% |
| 2010-12-31 | NT$18.64 Million ≈ $587.42K |
+176.39% |
| 2009-12-31 | NT$6.75 Million ≈ $212.54K |
-- |
About Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more